Health Canada has approved Ofev (nintedanib) as a treatment to slow the decline of pulmonary function in people with…
Articles by Patricia Inácio, PhD
Most people with scleroderma develop skin lesions within one year after the onset of Raynaud’s phenomenon (RP), a…
Treatment for one year with the immunosuppressant Cytoxan (cyclophosphamide) improves lung function in scleroderma patients with interstitial lung…
The European Scleroderma Trials and Research Group (EUSTAR) revised activity index scale, known as EUSTAR-AI, is the best tool…
Loss of muscle mass and strength — known as sarcopenia — may affect up to 55% of patients with systemic…
Levels of a pro-inflammatory signaling molecule, called interleukin (IL)-6, are significantly high in skin lesions and blood samples of patients…
Systemic sclerosis (SSc) patients with elevated protein in their urine (proteinuria) who are using angiotensin-converting enzyme (ACE) inhibitors (ACEi)…
Rituximab, an immunosuppressant antibody designed to target immune B cells, has widespread effects and decreases subtypes of other immune…
High levels of two proteins in the blood, called KL-6 and CCL-18, may work as biomarkers for predicting disease severity…
Tagraxofusp, a medicine approved in the U.S. under the name Elzonris to treat a rare blood cancer, may help…